MANAGEMENT OF ERECTILE DYSFUNCTION IN CARDIOVASCULAR PATIENTS WITH COMORBIDITIES: REVIEW OF THE TRIALS ON CONTINUING THERAPY WITH PHOSPHODIESTERASE-5 MEDICATIONS

The review is focused on the issues of erectile dysfunction (ED) management by long term courses of continuous intake of the phosphodiesteraze-5 type (PDE5) inhibitors. ED is an actual problem of modern healthcare, prevalent and influencing negatively life quality and interpersonal relations. At early stages the management of ED by the PDE5 inhibitor drugs was regarded as symptomatic. However recently there are more and more publications that confirm continuous long term intake of PDE5 inhibitors. This can be explained by the mechanism of this drugs class action that includes the causation of the disorder, particularly, endothelial dysfunction. It is well konwn that in erectile dysfunction there is malfunction of nitric oxide synthesis by endothelium, and long term usage of PDE5 facilitates the increase of biochemical reactions that can be started by nitric oxide. Based on the review data, a proposition made that PDE5 inhibitors are not harmful for cardiovascular system, but may present with positive effects on cardiovascular system in general. The trials towards this direction continue. There is also a suggestion that intake of PDE5 inhibitors helps to restore normal endothelial function that may lead to better condition of cardiovascular system and decrease complications rate.

1. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Importence Res 2000; 1 (12): 6-12.

2. Borlotti A, Parazzinin F, Collo E, Landoni M. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997; 20: 323-8.

3. Sharvadze GG, Mamedov MN, Poddubskaya EA, Kurbatov DG. Is erectile dysfunction a marker of cardiovascular diseases caused by atherosclerosis? Cardiovascular Therapy and Prevention 2010; 9 (7): 79-85. (In Russ.)

4. Ngai KH, Kwong AS, Wong AS, Tsui WW. Erectile dysfunction and lower urinary tract symptoms: prevalence and risk factors in a Hong Kong primary care setting. Hong Kong Med J 2013; 4: 311-6. DOI: 10.12809/hkmj133770.

5. Rosen RC, Fisher WA, Eardley I, et al. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in he general population. Curr Med Res Opin 2004; 20: 607-17. DOI: 10.1185/030079904125003467.

6. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999; 161: 5-11.

7. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 151-4.

8. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 1: 50-6.

9. Apolikhin OI, Krasnyak SS. Modern view on the relationship of erectile dysfunction and cardiovascular diseases. Experimental and clinical urology 2013; 4: 54-7. (In Russ.)

10. Pushkar DY, Kamalov AA, Al-Shukri SH, et al. Epidemiological study of the prevalence of erectile dysfunction in the Russian Federation. The Urals Medical J 2012; 3: 75-9. (In Russ.)

11. Mamedov MN, Digigova RT, Sharvadze GG, et al. Identification of erectile dysfunction and features of its treatment in men with a high risk of developing cardiovascular diseases and with coronary heart disease. Cardiology 2010; 11: 85-90. (In Russ.)

12. Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on Erectile Dysfunction: An Update Eur Urol 2006; 49: 806-15. DOI: 10.1016/j.eururo.2006.01.028.

13. Furchgott R F, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.

14. Krane RJ. Changes in ED therapy in the Viagra era. World J Urol 2001; 19: 23-4.

15. McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol 2006; 50: 215-7. DOI: 10.1016/j.eururo.2006.03.018.

16. Glina S, Sharlip ID, Hellstrom WJ. Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med 2013; 10: 115-9. DOI: 10.1111/j.1743-6109.2012.02816.

17. Brock G, Ni X, Oelke M, et al. Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases. J Sex Med 2016; 13 (5): 860-75. DOI: 10.1016/j.jsxm.2016.02.171.

18. Mazo EB, Gamidov SI, Iremashvili VV. Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernous arteries? A pilot study. BJU Int 2006; 98: 1054-8.

19. Sommer F, Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol 2005; 23: 85-92. DOI: 10.1007/s00345-005-0021-7.

20. Caretta N, Palego P, Ferlin A, et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol 2005; 48: 326-33. DOI: 10.1016/j.eururo.2005.01.013.

21. Markov KM. Molecular mechanisms of vascular endothelial dysfunction. Kardiologiia 2005; 12: 62-7. (In Russ.)

22. Park JW, Mrowietz C, Chung N, Jung F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo controlled, randomized cross over study. Clin Hemorheol Microcirc 2004; 31: 173-83.

23. Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. JACC 2002; 40: 1232-40.

24. Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214-20.

25. Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19: 200-7. DOI: 10.1038/sj.ijir.3901513.

26. Gamidov SI, Iremashvili VV. The effect of inhibitors of phosphodiesterase type 5 on the cardiovascular system. Diseases of the heart and blood vessels 2006; 2: 55-8. (In Russ.)